This trial is evaluating whether Treatment will improve 1 primary outcome and 4 secondary outcomes in patients with Atrial Fibrillation. Measurement will happen over the course of duration of ICU and hospital visit, up to 20 days.
This trial requires 150 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.